Document Detail

Lovastatin prevents development of hypertension in spontaneously hypertensive rats.
MedLine Citation:
PMID:  9336402     Owner:  NLM     Status:  MEDLINE    
The present study evaluated the effects of lovastatin on renal function and the development of hypertension in spontaneously hypertensive rats (SHR). Four-week-old SHR were given lovastatin (10 mg/kg) or vehicle twice daily by gavage. After 4 weeks of treatment, mean arterial pressure was significantly lower in lovastatin-treated SHR (131 +/- 4 mm Hg, n=5) than in control animals (160 +/- 4 mm Hg, n=12) (P<.05). The fall in arterial pressure in lovastatin-treated rats was accompanied by changes in renal function. The slope of the relationship between arterial pressure and sodium excretion was threefold greater in lovastatin-treated SHR (n=6) than in control rats (n=6), and this was associated with significant elevations in renal medullary blood flow and renal interstitial hydrostatic pressure. Glomerular filtration rate was 17% higher in lovastatin-treated SHR (n=6) than in control rats (n=6) (0.94 +/- 0.05 versus 0.81 +/- 0.07 mL/min per g of kidney weight, P<.05). The wall-to-lumen area ratio of renal arterioles was significantly reduced in lovastatin-treated SHR compared with vehicle-treated rats (0.86 +/- 0.05 versus 1.08 +/- 0.04 for vessels with inner diameters <50 microm and 0.62 +/- 0.02 versus 0.75 +/- 0.04 for vessels with inner diameters of 50 to 100 microm, P<.05). These results indicate that chronic treatment with lovastatin shifts the relations between renal medullary blood flow, renal interstitial pressure, sodium excretion, and renal perfusion pressure to lower levels of arterial pressure and attenuates the development of hypertension and renal vascular hypertrophy in SHR.
J Jiang; R J Roman
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Hypertension     Volume:  30     ISSN:  0194-911X     ISO Abbreviation:  Hypertension     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1997-11-13     Completed Date:  1997-11-13     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  968-74     Citation Subset:  IM    
Department of Physiology, Medical College of Wisconsin, Milwaukee 53226, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / pharmacology
Arterioles / pathology
Blood Pressure / drug effects
Extracellular Space / physiology
Glomerular Filtration Rate / drug effects
Hydralazine / pharmacology
Hydrostatic Pressure
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
Hypertension / genetics,  pathology,  prevention & control*
Kidney / drug effects,  physiopathology
Kidney Medulla / blood supply
Lovastatin / pharmacology*
Natriuresis / drug effects
Rats, Inbred SHR / physiology*
Renal Circulation / drug effects
Grant Support
Reg. No./Substance:
0/Antihypertensive Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 75330-75-5/Lovastatin; 86-54-4/Hydralazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of endogenous carbon monoxide in central regulation of arterial pressure.
Next Document:  Dynamic autoregulation and renal injury in Dahl rats.